Inquire About a Product| Product: | Hydroxy urea-13C,15N2 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Catalog Number: | CN27061 | ||||||||
| Synonyms: |
N-Hydroxyurea-13C,15N2; Biosupressin-13C,15N2; Carbamohydroxamic Acid-13C,15N2; Carbamoyl Oxime-13C,15N2; Cytodrox-13C,15N2; Droxia-13C,15N2; Hydrea-13C,15N2; Hydreia-13C,15N2; Hydroxycarbamide-13C,15N2 |
||||||||
| Pricing: |
|
||||||||
| Formula: | 13CH415N2O2 | ||||||||
| Enrichment: | 97% | ||||||||
| Chemical Purity: | 98% | ||||||||
| Molecular Weight: | 79.03 | ||||||||
| Structure: |
|
||||||||
| Category: | Labeled Reference Standards | ||||||||
| Literature References: |
Harrison CN, Campbell PJ, Buck G et al., Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N. Engl. J. Med., 2005, 353 (1): 33–45.; Lanzkron S, Strouse JJ, Wilson R et al., Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease. Ann. Intern. Med., 2008, 148 (12): 939–55. |
||||||||
| MSDS: | |||||||||
| Applications: | A labeled antineoplastic. Used to treat myeloproliferative disorders. Also used to reduce the rate of painful attacks in sickle-cell disease. Possesses antiretroviral properties in diseases such as HIV/AIDS. |